AVP
In the context of the launch of its Late Stage Fund, AVP continues to strengthen its leadership team to reinforce its global platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502656787/en/
(Photo: Business Wire)
First, after the recruitment of Elizabeth de Saint-Aignan in the USA, Warda's appointment in Europe completes the senior team of the new AVP Late Stage Fund.
Prior to joining AVP, Warda Shaheen held the position of Director at OMERS Growth Equity, where she conducted investments in prominent software companies such as Coveo, TouchBistro, PandaDoc, Clio, Celigo and GitLab. Previously, Warda worked in public markets at CPP Investments where she ran a $500M public markets portfolio in the thematic investing team. She also worked at Point72 Asset Management, Bain & Company and Deutsche Bank. Warda has experience working in the United States, Canada, United Kingdom, Singapore, Hong Kong and Germany. Warda holds an MSc in Financial Economics from the University of Oxford, a BESc in Mechanical Engineering from the University of Western University and an HBA in Business Administration the Richard Ivey School of Business.
Second, Pedro's appointment as Partner in charge of investor relations underlines AVP's objective of managing more capital for top tier institutional investors. Pedro brings extensive experience in fundraising of technology funds, from his tenure at Target Global, where he played a key role in fundraising multiple tech funds and fostering investor relationships. He has also held senior positions at MVision and Hamilton Lane. Having started his career in the venture capital arm of FINEP, the Brazilian innovation agency, Pedro holds an MBA and a BSc in Industrial Engineering from Pontifícia Universidade Católica do Rio de Janeiro.
“On behalf of the AVP team, I am delighted to extend a warm welcome to Warda and Pedro as our newest Partners. I am also very proud that AVP can attract such talents, and in the case of Warda, convince top tier investor in the North American market to come to Paris. Warda will play a key role in developing our new Late Stage Fund strategy, focusing on Europe. With this new Late Stage fund, we now have the capability to support entrepreneurs throughout their journey, from the early stages to IPO, as well as post-IPO, which sets us apart in the market. Warda brings extensive knowledge and a proven track record in investing in Late Stage companies in the US and in Europe. In the context of our platform expansion and ongoing fundraising efforts across various strategies, we are very happy to benefit from Pedro’s substantial fundraising experience of technology focused fund. His background at Target Global will undoubtedly add value to the entire AVP platform. At AVP, nothing is more important than the quality, the diversity and the complementarity of the team. Since 8 years, we have welcomed 9 Partners and are now ready to further expand the team with these two talents. No doubt that they will play a key role in the next chapter of our journey," commented François Robinet, Managing Partner at AVP.
“I am thrilled to become a part of the outstanding team of investors at AVP. Since I was introduced to the firm, I recognized this platform had the vision, skills, and leadership to amplify the global landscape of technology investing with a diverse partnership that leverages expertise across the financing spectrum. AVP's Late Stage strategy in Europe addresses several challenges in the European ecosystem, including the shortage of local funding for exceptional European technology leaders to expand globally. At AVP, we look forward to bringing our collective knowledge to support such leaders at various stages in both the private and public markets,” commented Warda Shaheen, General Partner at AVP.
“I am excited to join an incredibly talented team of investor at AVP. I have been fortunate to follow the development of the platform over the years and, now as part of the team, look forward to develop their robust capital base to attract additional top tier institutional investors globally,” commented Pedro Barros, Partner at AVP.
About AVP (AXA Venture Partners)
AVP (AXA Venture Partners) is a global venture capital firm specializing in high-growth, technology- enabled companies, managing more than $2 billion in assets across four investment strategies: Venture, Growth, Late Stage, and Fund of Funds. Since its establishment in 2016, AVP has invested in more than 60 technology companies in Venture and Growth stages in the US and Europe.
With offices in New York, London, and Paris, AVP supports companies in expanding internationally and provides portfolio companies with tailored business development opportunities to further accelerate their growth. AVP operates under AXA IM- Alts, the alternative investment business unit of AXA IM.
For more information, visit axavp.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502656787/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 01:00:00 CET | Press release
Stakeholder base expands with participation from an individual-investor-oriented fund, alongside corporate and individual investors, bringing Total Funding to USD 38M Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helic
Andersen Consulting udvider sin tilstedeværelse gennem samarbejde med Hilal Technology4.12.2025 23:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Hilal Technology for at styrke sine kompetencer inden for digital infrastruktur, cybersikkerhed og AI. Med tilstedeværelse i Bahrain, Saudi-Arabien, De Forenede Arabiske Emirater, Oman og Indien leverer Hilal Technology et komplet spektrum af digital infrastruktur og managed services inden for cloudcomputing, cybersikkerhed, enterprise ai og systemintegration. Deres ydelser omfatter cloudtjenester, sikkerheds- og netværksdrift, implementering af ERP og applikationer samt udvikling af generative ai-kapaciteter. Med et team på mere end 250 fagfolk servicerer firmaet en bred vifte af brancher, herunder den finansielle sektor, olie og gas, logistik og den offentlige sektor. "Transformation er mere end systemer; det handler om parathed, tillid og løbende samarbejde," udtaler Roshan George, direktør for Hilal Technology. "Vi er begejstrede for at samarbejde med Andersen Consulting og levere skalerbare løsninger, der matcher tempoet i den dig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
